CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
2017 · Nature Medicine · 1,313 citations
https://doi.org/10.1038/nm.4441
R
Robbie G. Majzner
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
233
Papers
12.5K
Citations
38
h-index
56
i10-index
Robbie G. Majzner is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: CAR-T cell therapy research & Virus-based gene therapy research & Cancer Research and Treatments. The author has an h-index of 38, co-authored 199 publications.
ORCID: 0000-0001-6969-8011Papers by this author
worksc-Jun overexpression in CAR T cells induces exhaustion resistance
2019 · Nature · 831 citations
https://doi.org/10.1038/s41586-019-1805-z
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
2022 · Nature · 751 citations
https://doi.org/10.1038/s41586-022-04489-4
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
2021 · Nature Medicine · 545 citations
https://doi.org/10.1038/s41591-021-01436-0
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
2022 · Nature Reviews Clinical Oncology · 450 citations
https://doi.org/10.1038/s41571-022-00704-3
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors
2020 · Nature Medicine · 296 citations
https://doi.org/10.1038/s41591-020-0821-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat